CSIMarket Company Name, Ticker, Suppliers, else..
 
Cytosorbents Corporation  (NASDAQ: CTSO)
 
Price: $0.3410 $0.00 1.488%
Day's High: $0.3440999984741211 Week Perf: -3.94 %
Day's Low: $ 0.32 30 Day Perf: -5.54 %
Volume (M): 111,591 52 Wk High: $ 1.04
Volume (M$): $ 0 52 Wk Avg: $0.64
Open: $0.32 52 Wk Low: $0.30



 Market Capitalization (Millions $) 21
 Shares Outstanding (Millions) 63
 Employees 129
 Revenues (TTM) (Millions $) 35
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 1

Business Description


Cytosorbents Corporation is a medical device company that specializes in blood purification technology. The company's flagship product, Cytosorb, is designed to remove harmful substances from the bloodstream, such as cytokines, toxins, and excessive fluids, in critically ill patients. The technology behind Cytosorb involves the use of highly porous polymer beads that adsorb these substances, helping to alleviate inflammation and organ dysfunction. Cytosorbents Corporation aims to improve patient outcomes and reduce the impact of severe conditions like sepsis, acute respiratory distress syndrome, and other life-threatening conditions.


   Company Address: 305 College Road East Princeton 8540 NJ
   Company Phone Number: 329-8885   Stock Exchange / Ticker: NASDAQ CTSO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX   -1.85%    
BDX   -1.38%    
CERS   -1.86%    
CSL   -4.4%    
HAE   -4.92%    
ICUI   -5.26%    
• View Complete Report
   



Stock Market Announcement

CytoSorbents Rights Offering: A Strategic Move for Shareholder Resilience Amid Market Volatility

Published Mon, Dec 23 2024 12:00 PM UTC

CytoSorbents Rights Offering Begins: Implications for ShareholdersIn a significant development for investors, CytoSorbents Corporation has announced the commencement of its rights offering, a strategic initiative aimed at enhancing the financial positioning of the company while offering eligible stockholders a unique opportunity to further stake their claim. According to th...
Stock Market Announcement

CytoSorbents Strategic Rights Offering: A Lifeline for Investors Amidst Volatile Share Performance

Published Mon, Dec 9 2024 12:01 PM UTC

In a pivotal move aimed at reinvigorating investor confidence and potentially stabilizing its fluctuating market performance, CytoSorbents Corporation has announced an exclusive rights offering for its existing stockholders. Investors who hold or purchase CTSO common stock by the market close on the upcoming Friday, December 13, 2024, stand to benefit from this initiative, s...
Product Service News

CytoSorbents Embarks on Canadian Approval Journey for DrugSorb-ATR Amid Financial Challenges

Published Mon, Nov 4 2024 12:00 PM UTC

CytoSorbents Corporation, a critical care immunotherapy company specialising in blood purification technology, has recently taken a significant step forward in its global expansion efforts. The company announced the submission of its DrugSorb-ATR Medical Device License Application to Health Canada. This milestone submission follows the successful completion of the Medical De...
Clinical Study

Balancing Innovation and Financial Hurdles CytoSorbents Journey with DrugSorb-ATR and Market Realities

Published Tue, Oct 1 2024 11:00 AM UTC

: This article provides a analysis of recent developments related to CytoSorbents Corporation s new product, DrugSorb-ATR, designed to mitigate bleeding risks in heart bypass surgery patients on ticagrelor. This novel therapy emerges amid a challenging financial landscape, marked by decreasing receivable collections and a competitive medical equipment industry. This analysi...
Shares

CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published Fri, Aug 16 2024 8:05 PM UTC



The CytoSorbents Corporation, a renowned player in the field of blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery, has recently made an important announcement. On August 14, 2024, the company granted inducement equity awards to its newly-hired Chief Financial Officer, Peter J. Mariani. This press rele...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.61
Price to Sales (Expected) -
Price to Book 9.75
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.3
Working Capital Ratio 1.09
Leverage Ratio (MRQ) 17.49
Total Debt to Equity 7.73
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.19 $
Revenues (TTM) 0.56 $
Cash Flow (TTM) -
Cash 0.08 $
Book Value 0.03 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 270,107
Net Income per Employee (TTM) -91,850
Receivable Turnover Ratio (TTM) 4.67
Inventory Turnover Ratio (TTM) 2.29
Asset Turnover Ratio (TTM) 0.78

Profitability Ratios Current
Gross Margin (MRQ) 75.4 %
Operating Margin (MRQ) -37.44 %
Net Margin (MRQ) -63.09 %
Net Cash Flow Margin (MRQ) -17.66 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Cytosorbents's Segments
United States    1.45 % of total Revenue
Germany    32.14 % of total Revenue
All other countries    75.44 % of total Revenue
Direct    59.73 % of total Revenue
Direct United States    1.45 % of total Revenue
Direct Germany    32.14 % of total Revenue
Direct All other countries    26.14 % of total Revenue
Distributors Strategic Partners    49.3 % of total Revenue
Distributors Strategic Partners All other countries    49.3 % of total Revenue
Single reportable segment    109.03 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.